Blauvelt A, Papp K, Gottlieb A, et al. - In this randomized, double-blinded study involving 1,027 patients with moderate-to-severe plaque psoriasis, researchers contrasted early and complete skin clearance by the interleukin (IL)-17A inhibitor ixekizumab vs the IL-23p19 inhibitor guselkumab using the Cochran-Mantel-Haenszel test with a multiple testing strategy. Participants in the study were patients randomized (1:1) to receive the approved dose of subcutaneous ixekizumab or guselkumab. In patients with moderate-to-severe plaque psoriasis by Week 12, ixekizumab was better than guselkumab for rapidly improving signs and symptoms. There were comparable adverse events to previous studies of ixekizumab and guselkumab. Ixekizumab can offer complete skin clearance more rapidly to patients with moderate-to-severe plaque psoriasis compared with the IL-23 inhibitor guselkumab.